Topics:

All Content

According to a report, two courses of the newly approved agent blinatumomab, for relapsed or refractory B-cell precursor ALL, will cost a staggering $178,000.

This slide show features some of the top highlights from the 2014 San Antonio Breast Cancer Symposium, including ovarian suppression in ER-positive breast tumors, tamoxifen for disease prevention, and immunotherapies for triple-negative breast cancer.

Researchers have identified several factors, including breastfeeding and oral contraceptives, that may decrease the risk of BRCA-associated ovarian cancer.

Long-term survival rates of patients after laparoscopic surgery for bladder cancer are similar to rates achieved with standard open surgery.

The US Food and Drug Administration approved lanreotide for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Risk for febrile neutropenia was high among patients with metastases from a variety of common cancers and was associated with numerous clinical and economic consequences, including increased morbidity and mortality.

Researchers have identified two new panRAF inhibitors that could be used to treat patients with BRAF- or NRAS-mutant melanoma, and those who have developed resistance to BRAF inhibitors.

A large trial showed that treatment-emergent vasomotor and/or joint symptoms do not correlate with any improvement in recurrence-free survival in postmenopausal breast cancer patients treated with aromatase inhibitors.

An analysis showed that etoposide-cisplatin or carboplatin-paclitaxel with RT yielded similar survival in patients with stage III non-small-cell lung cancer.

The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.